Yes, rivaroxaban 2.5 mg PO BID with aspirin 81 mg daily is an excellent regimen for patients with PAD
For patients with symptomatic peripheral arterial disease, the combination of rivaroxaban 2.5 mg twice daily plus aspirin 81 mg daily is a Class I (strong) recommendation based on the most recent 2024 ACC/AHA guidelines, as it effectively reduces both major adverse cardiovascular events (MACE) and major adverse limb events (MALE). 1
Why This Combination Works
The 2024 ACC/AHA guidelines represent a major shift from previous recommendations, now giving this dual-pathway inhibition strategy the highest level of recommendation (Class I) for symptomatic PAD patients. This is based on robust evidence showing:
- 24% reduction in MACE (cardiovascular death, MI, stroke) 1
- 46% reduction in MALE (acute limb ischemia, major amputation) 1
- Particularly effective post-revascularization with Class I recommendation after both endovascular and surgical procedures 1
The Canadian guidelines similarly provide a Strong Recommendation with High-Quality Evidence for this combination 2.
When to Use This Regimen
High-risk presentations where this combination is most beneficial:
- Symptomatic PAD (claudication, rest pain, ischemic ulcers)
- Post-revascularization (endovascular or surgical)
- Previous amputation
- Polyvascular disease (PAD plus coronary or cerebrovascular disease)
- Diabetes with PAD
- Heart failure with PAD
- Renal insufficiency (eGFR 15-60 mL/min) 2
Do NOT use in asymptomatic PAD - single antiplatelet therapy is sufficient for patients without symptoms 2
Critical Contraindications
Absolute contraindications to rivaroxaban 2.5 mg + aspirin:
- eGFR <15 mL/min
- Stroke within 1 month
- Any previous hemorrhagic stroke
- Strong CYP3A4 or p-glycoprotein inhibitors (e.g., ketoconazole, ritonavir)
- Active bleeding or high bleeding risk 2
Bleeding Risk vs Benefit
The bleeding trade-off is acceptable in most PAD patients:
- TIMI major bleeding increases modestly (HR 1.43) 3
- No increase in intracranial or fatal bleeding 4, 3
- Net clinical benefit strongly favors treatment: 70 fewer CV events per 10,000 patient-years vs 12 additional life-threatening bleeds 5
The 2024 ESC guidelines note this regimen should be considered for patients with non-high bleeding risk 6.
Practical Implementation
Dosing specifics:
- Rivaroxaban 2.5 mg PO BID (NOT the 10 mg or 20 mg doses used for other indications)
- Aspirin 81-100 mg daily
- Can be taken with or without food 5
- Continue long-term unless bleeding occurs 2
If clopidogrel is also needed (e.g., complex stenting):
- Triple therapy (rivaroxaban + aspirin + clopidogrel) can be used
- Limit clopidogrel to maximum 30 days to minimize bleeding risk
- Beyond 30 days, bleeding risk increases substantially (HR 3.20) 2
Alternative if Rivaroxaban Cannot Be Used
If the patient cannot receive rivaroxaban:
- Single antiplatelet therapy (aspirin 81 mg OR clopidogrel 75 mg) is reasonable 1
- After endovascular revascularization: DAPT (aspirin + clopidogrel) for 1-6 months 1
Bottom line: The rivaroxaban 2.5 mg BID + aspirin 81 mg daily combination is now the preferred evidence-based regimen for symptomatic PAD patients who are not at high bleeding risk, representing one of the most significant advances in PAD management in recent years.